Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1926-80-3

Post Buying Request

1926-80-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • METHYL 6-AMINOCAPROATE HYDROCHLORIDE CAS NO.1926-80-3

    Cas No: 1926-80-3

  • USD $ 7.0-8.0 / Metric Ton

  • 1 Metric Ton

  • 1000 Metric Ton/Day

  • KAISA GROUP INC
  • Contact Supplier

1926-80-3 Usage

Uses

Methyl 6-aminohexanoate is used as a reagent to synthesize straight chain hydroxamates, compounds that act as inhibitors of Human Histone Deacetylase (HDAC) that have the potential to treat cancer. Methyl 6-aminohexanoate is also sometimes used as a spacer unit for peptide synthesis.

Check Digit Verification of cas no

The CAS Registry Mumber 1926-80-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,9,2 and 6 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1926-80:
(6*1)+(5*9)+(4*2)+(3*6)+(2*8)+(1*0)=93
93 % 10 = 3
So 1926-80-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H15NO2.ClH/c1-10-7(9)5-3-2-4-6-8;/h2-6,8H2,1H3;1H

1926-80-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (07270)  Methyl6-aminohexanoatehydrochloride  ≥99.0% (AT)

  • 1926-80-3

  • 07270-25G

  • 2,458.17CNY

  • Detail
  • Sigma-Aldrich

  • (07270)  Methyl6-aminohexanoatehydrochloride  ≥99.0% (AT)

  • 1926-80-3

  • 07270-100G

  • 7,300.80CNY

  • Detail

1926-80-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 6-aminohexanoate,hydrochloride

1.2 Other means of identification

Product number -
Other names Methyl 6-aminohexanoate hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1926-80-3 SDS

1926-80-3Relevant articles and documents

Design, synthesis, and antiviral evaluation of phenanthrene-based tylophorine derivatives as potential antiviral agents

Wang, Kailiang,Hu, Yanna,Liu, Yuxiu,Mi, Na,Fan, Zhijin,Lieu, Yu,Wang, Qingmin

, p. 12337 - 12342 (2010)

A series of C9-substituted phenanthrene-based tylophorine derivatives (PBTs) were designed, synthesized, and first evaluated for their antiviral activities against tobacco mosaic virus (TMV). These compounds contain a phenanthrene core structure and can be synthesized some efficiently with excellent yields compared with tylophorine alkaloid. The bioassay results show that some of these compounds exhibited higher antiviral activity against TMV in vivo than tylophorine and commercial Ningnanmycin. Especially, compounds 3, 4, 9, 13, and 16 emerged as potential inhibitors of plant virus. These new findings demonstrate that these phenanthrene-based tylophorine derivatives (PBTs) represent another new template for antiviral studies and could be considered for novel therapy against plant virus infection.

Appraisal of pyrrole as connecting unit in hydroxamic acid based histone deacetylase inhibitors: Synthesis, anticancer evaluation and molecular docking studies

Patel, Vijay K.,Rajak, Harish,Singh, Avineesh

, (2021)

Pyrrole is a biologically active scaffold, which itself possess noticeable anticancer activity against several types of cancer specially leukemia, lymphoma, and myelofibrosis. SAHA and its synthetic analogs has demonstrated potent antitumor activity against numerous human cancer lines and different classes of HDACs. The HDAC inhibitor possessing pyrrole as linker moiety has been developed for anticancer property. The objective of present studies was to incorporate pyrrole as connecting unit in hydroxamic acid based HDAC inhibitors for their anticancer evaluation and molecular docking studies. A series of novel 4-substituted methyl 6-(3-acetyl-2-methyl-1H-pyrrol-1-yl)hexanoate [3(a-z)] and 4-substituted 6-(3-acetyl-2-methyl-1H-pyrrol-1-yl)-N-hydroxyhexanamide [4(a-z)] were synthesized. These analogs were evaluated for their anticancer activity using in-vitro method against leukemia (K-562), lung (A-549), breast (MCF-7), and cervical (HeLa) human cancer cell lines using Sulforhodamine B (SRB) assay method, HDAC1 and HDAC6 inhibitory assay and binding mode analysis using molecular docking studies. The in-vitro studies of 3(a-z) indicated that substitution with electron donating groups produces active or moderately active compounds. Interestingly, p-nitro-substituted molecule produced a most active derivative in the series. The in-vitro anticancer study of 4(a-z) indicated that the unsubstituted phenyl derivative, 6-(3-acetyl-2-methyl-4-phenyl-1H-pyrrol-1-yl)-N-hydroxy-hexanamide (4a) have moderate antitumor activity against K-562 human leukemia cell line. Substitution at 4-phenyl ring with weak and moderate electron withdrawing groups, such as fluoro, chloro, and bromo potentiated the cytotoxic activity. The 4(a-z)] were docked against different HDAC proteins to determine the exact binding mode and orientation. These synthetic analogs have similar binding mode as SAHA on the active pocket. The pyrrole based novel SAHA analogs 3(a-z) and 4(a-z) displayed promising anticancer activity. These studies can be further employed for the design and development of novel SAHA analogs with promising anticancer activity.

Histone deacetylase inhibitor as well as preparation and application thereof

-

Paragraph 0040-0041, (2021/04/28)

The invention relates to a histone deacetylase inhibitor and preparation and an application thereof, in particular to a novel histone deacetylase inhibitor based on a beta-elemene structure and a preparation method thereof, and further relates to an intermediate for synthesizing the histone deacetylase inhibitor and a preparation method thereof. The invention also relates to an application of the histone deacetylase inhibitor in preparation of antitumor drugs, and belongs to the technical field of chemical synthesis of drugs. The zinc ion combined compound and the salt or solvate thereof are shown as a general formula (I) or (II), wherein R, X, n and i are described in the claims and the specification.

Effect of Derivatives of Hydroxamic Acids on Vasculogenic Mimicry

Balaev, A. N.,Khachatryan, D. S.,Khochenkov, D. A.,Khochenkova, Yu. A.,Kolotaev, A. V.,Machkova, Yu. S.,Ohmanovich, K. A.,Osipov, V. N.,Vartanian, A. A.

, p. 252 - 263 (2020/05/04)

Abstract—: Vasculogenic mimicry, the formation of vascular channels lined with tumor cells of a highly malignant phenotype, is currently considered as an additional system of blood supply of the tumor. Experimental studies in vivo have repeatedly demonstrated that vascular channels form in the areas of a tumor with a low density of blood vessels. It is supposed that the formation of a network of these channels inside the tumor maintains homeostasis and prevents early necrosis within it. In this work, bifunctional compounds based on a combination of quinazoline and hydroxamic acid in one molecule were examined for the ability to inhibit the migration of tumor cells and vasculogenic mimicry.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1926-80-3